SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Treace Medical

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Treace Medical Concepts, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and undisclosed competition impacts on the company's primary product [3][5]. Group 1: Allegations and Impact - The complaint alleges that Treace Medical and its executives made false or misleading statements regarding the demand for their primary product, the Lapiplasty 3D Bunion Correction System, and failed to disclose competitive pressures affecting revenue [5]. - Following a press release on May 7, 2024, the company lowered its full-year 2024 revenue guidance from a range of $220 million to $225 million down to $201 million to $211 million, indicating significant revenue decline [6]. - The stock price of Treace Medical fell by $6.95, or nearly 63%, closing at $4.17 per share on May 8, 2024, following the announcement of the lowered revenue guidance [7]. Group 2: Legal Proceedings - Investors who purchased Treace Medical securities between May 8, 2023, and May 7, 2024, are encouraged to discuss their legal rights and options, with a deadline of June 10, 2025, to seek the role of lead plaintiff in the federal securities class action [2][3]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [8]. - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Treace's conduct [9].